Blau Farmacêutica Balance Sheet Health
Financial Health criteria checks 6/6
Blau Farmacêutica has a total shareholder equity of R$2.2B and total debt of R$509.5M, which brings its debt-to-equity ratio to 23.3%. Its total assets and total liabilities are R$3.4B and R$1.2B respectively. Blau Farmacêutica's EBIT is R$400.5M making its interest coverage ratio 26.8. It has cash and short-term investments of R$442.1M.
Key information
23.29%
Debt to equity ratio
R$509.51m
Debt
| Interest coverage ratio | 26.8x |
| Cash | R$442.10m |
| Equity | R$2.19b |
| Total liabilities | R$1.24b |
| Total assets | R$3.43b |
Recent financial health updates
Blau Farmacêutica (BVMF:BLAU3) Has A Pretty Healthy Balance Sheet
Mar 21
Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?
Dec 04Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?
Jun 28Recent updates
Latin America Expansion And R&D Will Unlock New Markets
Strategic LatAm expansion and international partnerships are set to boost revenue and expand market share across multiple countries.Blau Farmacêutica (BVMF:BLAU3) Has A Pretty Healthy Balance Sheet
Mar 21Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?
Dec 04Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 07Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up
Nov 06Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings
Aug 29Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?
Jun 28Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop
Feb 01What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates
May 14Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Feb 24Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely
Oct 14Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)
Aug 17Financial Position Analysis
Short Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its short term liabilities (R$510.1M).
Long Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its long term liabilities (R$733.9M).
Debt to Equity History and Analysis
Debt Level: BLAU3's net debt to equity ratio (3.1%) is considered satisfactory.
Reducing Debt: BLAU3's debt to equity ratio has reduced from 93.5% to 23.3% over the past 5 years.
Debt Coverage: BLAU3's debt is well covered by operating cash flow (87.7%).
Interest Coverage: BLAU3's interest payments on its debt are well covered by EBIT (26.8x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 01:42 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Blau Farmacêutica S.A. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Frederico Mendes | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Samuel Campos Alves | BTG Pactual |